[go: up one dir, main page]

NO932672D0 - Monokloane antistoffer mot elam-1 og anvendelser derav - Google Patents

Monokloane antistoffer mot elam-1 og anvendelser derav

Info

Publication number
NO932672D0
NO932672D0 NO932672A NO932672A NO932672D0 NO 932672 D0 NO932672 D0 NO 932672D0 NO 932672 A NO932672 A NO 932672A NO 932672 A NO932672 A NO 932672A NO 932672 D0 NO932672 D0 NO 932672D0
Authority
NO
Norway
Prior art keywords
monocloan
applications
antibodies against
against elam
elam
Prior art date
Application number
NO932672A
Other languages
English (en)
Other versions
NO932672L (no
Inventor
Elisabeth Wayner
Mary L Phillips
Jeffrey L Winkelhake
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of NO932672D0 publication Critical patent/NO932672D0/no
Publication of NO932672L publication Critical patent/NO932672L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO93932672A 1991-01-24 1993-07-23 Monokloane antistoffer mot elam-1 og anvendelser derav NO932672L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US73303391A 1991-07-22 1991-07-22
PCT/US1992/000577 WO1992012729A1 (en) 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses

Publications (2)

Publication Number Publication Date
NO932672D0 true NO932672D0 (no) 1993-07-23
NO932672L NO932672L (no) 1993-09-23

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932672A NO932672L (no) 1991-01-24 1993-07-23 Monokloane antistoffer mot elam-1 og anvendelser derav

Country Status (11)

Country Link
EP (1) EP0568631A4 (no)
JP (1) JPH06505253A (no)
AU (1) AU1269092A (no)
CA (1) CA2100681A1 (no)
IE (1) IE920206A1 (no)
IL (1) IL100764A0 (no)
NO (1) NO932672L (no)
NZ (1) NZ241399A (no)
OA (1) OA09809A (no)
SK (1) SK77393A3 (no)
WO (1) WO1992012729A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
EP0627940B1 (en) * 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
IL140700A0 (en) 1998-07-13 2002-02-10 Univ Texas Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
TR200101757T2 (tr) 1998-12-18 2001-12-21 Dupont Pharmaceuticais Company Vitronektin reseptör antagonisti farmasötikler
AU766822B2 (en) 1998-12-18 2003-10-23 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP2328920A2 (en) * 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US11597770B2 (en) 2020-01-24 2023-03-07 Pfizer Inc. Anti-E-selectin antibodies, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002860A1 (en) * 1988-11-14 1990-05-14 Michael A. Gimbrone Antibodies specific for elam-1 and the use thereof
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
OA09809A (en) 1994-04-15
CA2100681A1 (en) 1992-07-25
WO1992012729A1 (en) 1992-08-06
JPH06505253A (ja) 1994-06-16
IL100764A0 (en) 1992-09-06
IE920206A1 (en) 1992-07-29
NO932672L (no) 1993-09-23
SK77393A3 (en) 1994-12-07
AU1269092A (en) 1992-08-27
EP0568631A4 (en) 1995-04-05
NZ241399A (en) 1994-06-27
EP0568631A1 (en) 1993-11-10

Similar Documents

Publication Publication Date Title
NO932672D0 (no) Monokloane antistoffer mot elam-1 og anvendelser derav
NO921863L (no) Antistoffer og anvendelse derav
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
DK145493D0 (da) Antistof
NO922118D0 (no) Kabelskjoeter og kabelavslutninger
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
DE69422259D1 (de) Verbindungseinrichtung
DE69422258D1 (de) Verbindungseinrichtung
FI923892A (fi) Strukturella element foer en kaernreaktors braenslestavsmontering
DE69212819D1 (de) Aufbaumethode und -vorrichtung
NO943167D0 (no) Modifisert TCF
BR9406795A (pt) Transdutor
NO873017L (no) Antistoffer mot c5a og anvendelser derav.
DE69401310D1 (de) Verbindungsvorrichtung
BR9205281A (pt) Pentapeptideos imuno-reguladores e neuro-reguladores
DE69329125D1 (de) Dekodiervorrichtung
DE59303655D1 (de) Messwandler
NO954403D0 (no) Antistoffer mot P-selektin og deres anvendelse
DE69405331D1 (de) Verbindungsvorrichtung
DE69405332D1 (de) Verbindungsvorrichtung
KR950005963U (ko) 앨범
KR930002921U (ko) 메카니컬시일링 장치
FI837U1 (fi) Skydd mot aelgflugor
DK90092D0 (da) Bukkenoeglesaet i og bukkenoeglesaet ii
DK251090D0 (da) Antistoffer og anvendelse deraf